Abstract:Background Rheumatoid arthritis (RA) is a progressive immune-mediated disease that can culminate in joint destruction and early mortality. High levels of serum RF are associated with a worse prognosis in RA. The role of is not fully understood. Recently, Our studies have found that the absolute number of peripheral CD4 + CD25 + Foxp3 + regulatory T (CD4 + Treg) cells decreased in RA patients. Interestingly, regulatory T cell epitopes (Tregitopes) in IgG have been reported as the main component of intravenous immunoglobulin therapy (IVIG) and provide one explanation for the expansion and activation of Treg cells following IVIg treatment. We hypothesise that RF joins with IgG to form large molecular complexes, which interrupts the production of Tregitopes in antigen presenting cells as a cause of reduction of CD4 + Treg cells. Objectives The aim of this study is to investigate whether the absolute number of CD4 + Treg cells is associated with the titers of auto-antibodies in blood of new-onset diagnosed patients with RA. Methods A total of 57 new-onset diagnosed patients with RA were enrolled and healthy donors as control. The absolute number of peripheral CD4 + Tregs cells was detected by multicolor flow cytometry combined with an internal microsphere counting standard. 46 of new-onset cases were tested the levels of RF and anti-CCP with ELISA method. IIF method was used to detect APF and AKA. Low titers group and high titers group around with the value 1:80. All data was analysed by SPSS 22.0. Results The absolute number of CD4 + Treg cells in peripheral blood of new-onset patients with RA was significantly lower than in healthy controls [25.1 (16.01, 40.75) vs 33.0567 (22.9, 43.18), p + Treg cells was negatively correlated to RF titers (correlation coefficient −0.488, p + Tregs in high titers RF group was lower than in low titers RF group [20.5 (14.0,40.0 vs 34.0 (29.7,44.6),p Conclusions The absolute number of CD4 + Treg cells in peripheral blood of new-onset patients with RA was significantly decreased compared with that in health controls. Furthermore, the reduction of peripheral CD4 + Treg cells was negatively correlated to the titers of RF, suggesting that RF contributes to the reduction of CD4 +Tregs cells. The correlation of decreased CD4 + Treg and RF may be involved in the pathogenesis of poor prognosis in RA. Reference [1] Cousens LP, Najafian N, Mingozzi F, Elyaman W, Mazer B, Moise L, Messitt TJ, Su Y, Sayegh M, High K, Khoury SJ, Scott DW, De Groot AS. In vitro and in vivo studies of IgG-derived Treg epitopes (Tregitopes): a promising new tool for tolerance induction and treatment of autoimmunity. J Clin Immunol2013Jan;33(Suppl 1):S43–9. doi:10.1007/s10875-012-9762-4 [Epub 2012 Sep 2. Review]. Disclosure of Interest None declared

Modeling of antibody responses to COVID-19 vaccination in patients with rheumatoid arthritis

Determination of the factors associated with antigen-specific CD4+ T-cell responses to BNT162b2 in patients with rheumatoid arthritis

Immunogenicity of Inactivated SARS-CoV-2 Vaccines in Patients With Rheumatoid Arthritis: A Case Series

SARS-CoV-2 mRNA vaccine-induced immune responses in rheumatoid arthritis

Effectiveness and Safety of the COVID-19 Vaccine in Patients with Rheumatoid Arthritis in a Real-World Setting

Escalating SARS-CoV-2 specific humoral immune response in rheumatoid arthritis patients and healthy controls

Diminished antibody response to SARS‐CoV‐2 in rheumatoid arthritis compared to metabolic disorders following the primary series of vaccinations and its recovery with a booster: A single‐center prospective observational study

Immune responses and disease biomarker long-term changes following COVID-19 mRNA vaccination in a cohort of rheumatic disease patients

The serological immunogenicity of the third and fourth doses of COVID-19 vaccine in patients with inflammatory rheumatic diseases on different biologic or targeted DMARDs: a Swedish nationwide study (COVID-19-REUMA)

Analysis of T-cell and Humoral Immune Response to SARS-CoV-2 Antigens in Rituximab-Treated Patients with Rheumatoid Arthritis Vaccinated with Combined Vector Vaccine Gam-COVID-Vac

Increased Risk of COVID‐19 in Patients with Rheumatoid Arthritis: A General Population‐Based Cohort Study

Modeling how antibody responses may determine the efficacy of COVID-19 vaccines

Postvaccination antibody titres predict protection against COVID-19 in patients with autoimmune diseases: survival analysis in a prospective cohort

Dynamics of SARS-CoV-2 immunity after vaccination and breakthrough infection in rituximab-treated rheumatoid arthritis patients: a prospective cohort study

Anti-RBD IgG dynamics following infection or vaccination

SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study

AB0321 Negative correlation of the absolute number of cd4 +cd25+foxp3+regulatory t cells to the levels of rheumatoid factor in peripheral blood of new onset patients with rheumatoid arthritis

Determinants of SARS-CoV-2 IgG response and decay in Canadian healthcare workers: A prospective cohort study

Determinants of health as predictors for differential antibody responses following SARS-CoV-2 primary and booster vaccination in an at-risk, longitudinal cohort

Comparison of SARS-COV-2 humoral response between rheumatoid arthritis, psoriatic arthritis and spondyloarthritis patients and controls in two unvaccinated cohorts

COVID-19 Vaccination in Patients with Autoimmune Inflammatory Rheumatic Diseases: Clinical Guidance of the Korean College of Rheumatology